Retatrutide 20 mg — Research Peptide
Retatrutide is a next-generation triple-agonist research peptide that activates GLP-1, GIP and glucagon receptors simultaneously. This unique triple-receptor activity makes it the most potent GLP-1-based compound in current clinical research.
Product Details
- Net weight: 20 mg (lyophilised)
- Purity: ≥98.9% (HPLC-verified)
- Identity confirmed by LC-MS
- Batch-specific COA included
For research purposes only. Not intended for human use.
Reviews
There are no reviews yet.